CVRx, Inc. is a commercial-stage medical device company. Co. is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. Co.'s integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. The CVRX average annual return since 2021 is shown above.
The Average Annual Return on the CVRX average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CVRX average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CVRX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free CVRX Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
